Axsome Therapeutics
Yahoo Finance • 2 days ago
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and confer... Full story
Yahoo Finance • 2 days ago
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours 85% and 77% of patients treated with a single dose of SYMBRAVO did not req... Full story
Yahoo Finance • 3 months ago
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
How richly valued are stocks right now? Legendary investor Warren Buffett has built Berkshire Hathaway's cash stockpile up to roughly $277 billion. When Buffett is sitting on that much cash because he can't find appealing investments to bu... Full story
Yahoo Finance • 9 months ago
3 Monster Stocks in the Making You Can Buy Right Now
If you go to California's Redwood National Park, you can see the world's tallest tree -- a redwood called Hyperion that's over 380 feet tall. Like every other tree, though, Hyperion started as a small seed. Stocks can be like this, beginn... Full story
Yahoo Finance • 9 months ago
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics, Inc. NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disord... Full story
Yahoo Finance • 9 months ago
Axsome Therapeutics Inc (AXSM) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues ...
Total Net Product Revenue: $75 million in Q1 2024, up 160% year-over-year. Net Product Sales: $74.1 million in Q1 2024. Royalty Revenue: $900,000 in Q1 2024. Ability Net Product Sales: $53.4 million in Q1 2024, up 240% year-over-year. Suno... Full story
Yahoo Finance • 10 months ago
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Price matters. That's true whether we're talking about cars, houses, laptops, or anything else -- including stocks. Three Motley Fool contributors had price in mind when choosing Axsome Therapeutics(NASDAQ: AXSM), CRISPR Therapeutics(NASD... Full story
Yahoo Finance • 11 months ago
11 Oversold NASDAQ Stocks To Buy Right Now
In this article, we will be taking a look at 11 oversold NASDAQ stocks to buy right now. To skip our detailed analysis of current stock market news, you can go directly to see the 5 Oversold NASDAQ Stocks To Buy Right Now. NASDAQ Leads Th... Full story
Yahoo Finance • 11 months ago
3 Biotech Stocks to Buy and Hold for the Next 10 Years
The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely eradicate diseases, which doesn't seem li... Full story
Yahoo Finance • 12 months ago
Breakeven On The Horizon For Axsome Therapeutics, Inc. (NASDAQ:AXSM)
With the business potentially at an important milestone, we thought we'd take a closer look at Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) future prospects. Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development o... Full story
Yahoo Finance • last year
Investing in Axsome Therapeutics (NASDAQ:AXSM) five years ago would have delivered you a 796% gain
Buying shares in the best businesses can build meaningful wealth for you and your family. And highest quality companies can see their share prices grow by huge amounts. Just think about the savvy investors who held Axsome Therapeutics, Inc... Full story
Yahoo Finance • last year
Prediction: These 3 Stocks Will Soar in 2024
No person knows for sure what the future will hold for stocks in the new year. However, it can be fun to attempt to predict what might happen. Three Fool.com contributors have done just that. Here's why they think that Axsome Therapeutics... Full story
Yahoo Finance • last year
Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Shareholders to Contact the Firm
NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Axsome Therapeutics, Inc. (“Ax... Full story
Yahoo Finance • last year
Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) in... Full story
Yahoo Finance • last year
AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. (“Axsome”) (NASDAQ: AXSM) of the reopening of the lead plaintiff appo... Full story
Yahoo Finance • last year
11 Best Upside Stocks To Buy Right Now
In this piece, we will take a look at the 11 best upside stocks to buy right now. If you want to skip our overview of share valuation, then take a look at the 5 Best Upside Stocks To Buy Now. The art of buying shares on the market has alw... Full story
Yahoo Finance • last year
AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. (“Axsome”) (NASDAQ: AXSM) of the reopening of the lead plaintiff appo... Full story
Yahoo Finance • last year
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced tha... Full story
Yahoo Finance • last year
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced tha... Full story
Yahoo Finance • last year
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the reopening of the lead plaintiff appointment process in a class action lawsuit against Axsome Therapeutics, Inc. (“Axsome”... Full story
